AL Amyloidosis - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

AL Amyloidosis Emerging Therapy and TPP Insights

Thelansis's "AL Amyloidosis Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

AL Amyloidosis Overview

AL amyloidosis is a life-threatening plasma cell disorder in which clonal immunoglobulin light chains misfold into amyloid fibrils that deposit in organs and cause progressive dysfunction. Cardiac and renal involvement produce restrictive cardiomyopathy, heart failure, and nephrotic proteinuria; macroglossia, purpura, and neuropathy may occur. Diagnosis requires tissue biopsy with Congo red birefringence and typing plus serum and urine immunofixation and free light chain assays. Treatment prioritizes rapid hematologic response, typically daratumumab with bortezomib, cyclophosphamide and dexamethasone; autologous stem cell transplant is reserved for selected fit patients.

Key Highlights

• In the United States, incident AL Amyloidosis cases are projected to increase from 5,209 in 2025 to 5,602 by 2035.
• AL Amyloidosis is a rare and progressive systemic disorder associated with significant organ dysfunction and reduced survival.
• Delayed diagnosis remains a major challenge due to the heterogeneous and non-specific nature of disease presentation.
• Despite recent therapeutic advances, substantial unmet need persists for treatments capable of improving organ responses and long-term survival.

Market Overview

• The Germany AL Amyloidosis market is projected to grow from $50M in 2025 to $110M by 2035.
• Market growth is driven by:
• Increasing adoption of novel plasma cell-directed therapies and combination treatment regimens
• Improved disease recognition and expanding diagnostic capabilities
• Future growth will depend on therapies capable of achieving durable hematologic responses while promoting organ recovery and disease modification.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Alexion Pharmaceuticals, Inc.
• Nexcella Inc.
• Lantheus Germany GmbH
• Janssen Research & Development, LLC
• Nanjing IASO Biotechnology Co., Ltd.
• Gracell Biotechnologies (Shanghai) Co., Ltd.
• AbbVie